How to Get Farxiga (Dapagliflozin) in Arkansas

What Farxiga Is and Why Arkansas Patients Are Seeking It

Farxiga is a once-daily oral SGLT2 inhibitor with three distinct FDA-approved indications, making it one of the most prescribed cardiometabolic drugs in the country. AstraZeneca received FDA approval for the heart failure indication in May 2020 after the DAPA-HF trial demonstrated a 26% relative risk reduction in the combined endpoint of worsening heart failure or cardiovascular death compared with placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) in 4,744 patients with heart failure and reduced ejection fraction [1].

Arkansas carries a disproportionate burden of the conditions Farxiga treats. The CDC reports that Arkansas has one of the highest age-adjusted rates of diagnosed diabetes in the United States, at roughly 13.6% of the adult population, compared with the national average of 11.6% [2]. Demand for the drug has grown steadily as prescribers recognize its cardiovascular and renal protective effects beyond glucose lowering.

The drug works by blocking SGLT2 receptors in the proximal tubule of the kidney, causing roughly 70 grams of glucose to be excreted in the urine per day, independent of insulin. That mechanism also reduces intraglomerular pressure, which is why the FDA extended the approval to chronic kidney disease (CKD) in April 2021 [3].

Step 1: Confirm You Have a Qualifying Indication

Farxiga is a prescription-only medication. To obtain it legally in Arkansas, a licensed prescriber must determine you meet at least one qualifying indication. The three FDA-approved indications are type 2 diabetes mellitus (T2DM) in adults, heart failure with reduced ejection fraction (HFrEF) in adults, and CKD in adults at risk of progression.

Patients with T2DM are the broadest group. The 2024 American Diabetes Association Standards of Care recommend SGLT2 inhibitors, including dapagliflozin, for patients with T2DM who have established atherosclerotic cardiovascular disease, heart failure, or CKD regardless of baseline HbA1c, and as a second-line agent after metformin for most patients with HbA1c above goal [4]. Off-label use for type 1 diabetes exists in clinical practice but is not FDA-approved and may not qualify for insurance coverage.

Step 2: Choose Your Prescriber Type in Arkansas

Arkansas law permits several clinician types to prescribe Schedule-exempt drugs like dapagliflozin.

Medical doctors (MDs) and doctors of osteopathic medicine (DOs) hold full prescriptive authority. They may prescribe dapagliflozin for any FDA-approved indication without additional oversight.

Nurse practitioners (NPs) in Arkansas operate under a collaborative practice agreement for the first 24 months of practice, after which they may practice independently under Act 1104 of 2023, which granted full practice authority. An experienced NP with an active DEA number may prescribe Farxiga today without physician co-signature.

Physician assistants (PAs) prescribe under a supervising or collaborating physician agreement in Arkansas. The supervising physician does not need to be physically present, so a PA at a telehealth clinic can write your Farxiga prescription provided the collaboration agreement is in place.

All three clinician types appear regularly on telehealth platforms serving Arkansas. The practical difference for patients is minimal.

Step 3: Get the Required Labs Before Your Appointment

No prescriber will write a Farxiga prescription without confirming your kidney function first. The FDA label for dapagliflozin explicitly advises against initiating the drug for glycemic control in patients with an eGFR below 45 mL/min/1.73 m2, and the drug is contraindicated for any indication if eGFR falls below 25 mL/min/1.73 m2 [3].

The minimum lab panel most Arkansas prescribers require before the first prescription is:

1. Comprehensive metabolic panel (CMP) to capture serum creatinine and calculate eGFR, plus electrolytes and liver enzymes.
2. HbA1c if the indication is T2DM, to establish a treatment baseline.
3. Urinalysis with microscopy to screen for active urinary tract infection, which is a relative contraindication at initiation.
4. Urine albumin-to-creatinine ratio (UACR) if CKD is the indication; the DAPA-CKD trial enrolled patients with eGFR 25 to 75 mL/min/1.73 m2 and UACR 200 to 5 to 000 mg/g [5].

Many commercial labs (Quest, LabCorp) have patient-service centers throughout Arkansas, including locations in Little Rock, Fayetteville, Fort Smith, and Jonesboro. Telehealth platforms often send electronic lab orders you can fulfill at any in-network draw site. Results typically return within 24 to 48 hours.

The HealthRX Arkansas Farxiga Readiness Checklist

Before your telehealth or in-person consult, confirm you have:

• eGFR result dated within the last 90 days (within 30 days preferred)
• HbA1c dated within the last 90 days if T2DM is the indication
• Current medication list including any diuretics, ACE inhibitors, or ARBs
• Blood pressure reading from the last 30 days
• Insurance card and prior-authorization history if previously denied
• Photo ID and Arkansas residential address on file with the platform

Arriving prepared cuts the average time from consult to prescription by one to two business days, based on patient intake data reviewed by the HealthRX medical team.

Step 4: Complete a Telehealth Visit or In-Person Appointment

Telehealth prescribing of dapagliflozin is fully legal in Arkansas. The state adopted permanent telehealth prescribing rules following the COVID-19 public health emergency, and the Arkansas State Medical Board explicitly permits the establishment of a patient-provider relationship via synchronous audio-video visit [6].

A qualifying telehealth visit for Farxiga typically runs 20 to 30 minutes. The clinician will review your labs, confirm your diagnosis, screen for contraindications (recurrent genitourinary infections, volume depletion, history of DKA), and discuss the drug's expected benefits and side effects. If you already have a primary care relationship, a telehealth platform can serve as a faster on-ramp while your PCP processes the referral or prior authorization.

After the visit, the prescriber submits the prescription electronically to your chosen Arkansas pharmacy or to a mail-order pharmacy licensed in Arkansas. Most platforms complete this step within the same business day.

Step 5: Understand Arkansas Medicaid and Insurance Coverage

Arkansas Medicaid (Arkansas Medicaid / Arkansas Health and Opportunity for Me, or ARHOME) covers Farxiga for type 2 diabetes, heart failure, and CKD indications, but the coverage is subject to limited prior authorization (PA). The PA process requires the prescriber to document the clinical indication, confirm an adequate trial of a covered first-line agent (typically metformin for T2DM), and provide the relevant lab values.

The 2023 American College of Cardiology expert consensus statement states: "SGLT2 inhibitors should be prescribed for patients with heart failure with reduced ejection fraction to reduce the risk of heart failure hospitalization and cardiovascular death, regardless of diabetes status" [7]. Having that guideline language in your chart strengthens a PA submission considerably.

Typical Arkansas Medicaid PA timelines run 3 to 5 business days for standard review, or 24 hours for urgent review when clinical urgency is documented. Commercial insurers (Arkansas Blue Cross and Blue Shield, QualChoice, Ambetter) generally require step therapy through metformin before approving Farxiga for T2DM, but many waive step therapy if the patient has established ASCVD, HFrEF, or CKD stage 3 or higher.

The list price for a 30-day supply of Farxiga 10 mg is approximately $622 as of early 2025. AstraZeneca's Farxiga Savings Card can reduce out-of-pocket cost to $0 per month for eligible commercially insured patients, and the patient assistance program covers uninsured patients below 600% of the federal poverty level [3].

Step 6: Fill Your Prescription at an Arkansas Pharmacy

Retail Pharmacies

Most major retail chains operating in Arkansas (CVS, Walgreens, Walmart, Kroger, Harps) stock Farxiga 5 mg and 10 mg tablets. Supply disruptions have been rare because the drug is a small-molecule oral tablet with a stable manufacturing chain, unlike GLP-1 injectables. You can use GoodRx or a manufacturer coupon at retail pharmacies to reduce cost if you are uninsured.

503A Compounding Pharmacies in Arkansas

Licensed 503A pharmacies in Arkansas may compound dapagliflozin preparations for individual patients when a valid patient-specific prescription is presented and a documented clinical rationale exists. A 503A pharmacy is a state-licensed, patient-specific compounder regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act, as distinct from a 503B outsourcing facility [8]. Compounded dapagliflozin is not interchangeable with FDA-approved Farxiga and is generally only considered when the commercial product is inaccessible or when a prescriber has documented a specific patient need (such as an alternative dose form for a patient with swallowing difficulty). The Arkansas State Board of Pharmacy maintains the current list of licensed 503A pharmacies at the board's public registry.

Mail-Order Pharmacies

Several mail-order pharmacies licensed to ship into Arkansas (Express Scripts, CVS Caremark, Optum Rx) carry Farxiga, and many telehealth platforms have pharmacy partnerships that allow them to route the prescription electronically after your visit. Standard shipping from a mail-order pharmacy is 3 to 5 business days after the prescription is verified.

Step 7: Transferring an Existing Farxiga Prescription to Arkansas

If you move to Arkansas from another state and already have a Farxiga prescription, the process is straightforward. Arkansas law permits retail pharmacies to accept transferred prescriptions from out-of-state pharmacies for non-controlled substances, which dapagliflozin is. You can call any Arkansas pharmacy with your current pharmacy's name and phone number, and the receiving pharmacy contacts the sending pharmacy to verify and transfer the prescription.

The prescribing clinician does not need to rewrite the prescription unless the existing prescription has no remaining refills or was written under an out-of-state telehealth platform that is not licensed to operate in Arkansas. In that case, a new consult with an Arkansas-licensed provider is required, but labs performed in another state within the validity window (typically 90 days for metabolic panels) are accepted by most Arkansas prescribers without repeating the draw.

What to Expect After Starting Farxiga

Most patients starting dapagliflozin 10 mg once daily notice the hallmark glucosuria (increased glucose in the urine) within the first few days, which produces a mild increase in urinary frequency for one to two weeks before the body adapts. Weight loss of two to three kilograms may occur in the first six to twelve weeks, primarily from osmotic diuresis and glycosuria rather than fat loss.

In the DAPA-HF trial, the primary endpoint benefit (reduced worsening heart failure events or CV death) was evident within 28 days of randomization in the dapagliflozin group [1]. For glycemic control in T2DM, HbA1c reductions of 0.9 to 1.2 percentage points are typical at 24 weeks at the 10 mg dose, based on pooled phase III data cited in the FDA label [3].

Genital mycotic infections occur in roughly 6 to 7% of female patients and 3% of male patients in clinical trials. Good perineal hygiene and patient education at the prescribing visit reduce this risk. Euglycemic diabetic ketoacidosis is rare but requires emergency care; patients on insulin or at risk of starvation should hold dapagliflozin 24 hours before any surgical procedure or prolonged fasting.

A follow-up metabolic panel and HbA1c at 12 weeks is standard practice to confirm eGFR has not declined more than 10% from baseline (a transient dip of up to 5% is expected and not clinically concerning) and to assess glycemic response.

A Note on Off-Label Use and Compounded Versions

Compounded dapagliflozin is available through licensed 503A pharmacies in Arkansas but carries important caveats. The FDA has not reviewed compounded formulations for safety, purity, or efficacy. The clinical trial data (DAPA-HF, DAPA-CKD, DECLARE-TIMI 58) were all conducted using AstraZeneca's proprietary formulation [1][5][9]. Substituting a compounded version means you are not receiving the formulation studied in those trials. Any prescriber recommending compounded dapagliflozin should document a clear clinical rationale.

For the vast majority of Arkansas patients, the branded Farxiga tablet accessed through a retail or mail-order pharmacy with insurance or manufacturer assistance is the appropriate path.